56 /100
HIGH RISK
Score updated May 30, 2026

NRXP — NRx Pharmaceuticals, Inc. Dilution Risk Tracker

Track NRXP dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track NRXP — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
60
💰 Cash Runway
65
📊 Float Risk
15
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

🌥️
Advisory
Moderate dilution signals present
31%
📉 Score Deterioration 40%
• Score rose 37 points recently (worsening)
💰 Capital Raise 33%
• Under 12 months cash (9mo)
• Active ATM program with $20M remaining capacity
🔄 Reverse Split 10%
• 9 months cash with weak price
🔔 Track NRXP — Get forecast alerts →

💹 Market Data

Market Cap$160.13M
Shares Outstanding36.23M
Float30.45M
Cash$6.71M
Debt$934.0K
Short InterestN/A

🏛 Institutional Holdings

QoQ: ↑ 31.9% shares (2025Q4 vs prior)
30 institutional holders · 5.33M shares
#1 Anson Funds Management LP 3.04M shares
#2 VANGUARD GROUP INC 729.8K shares
#3 COMMONWEALTH EQUITY SERVICES, LLC 366.6K shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest4.67M
Days to Cover4.2
% of Float15.3%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL WARRANT Dec 31, 2025
xbrl XBRL CONVERTIBLE Dec 31, 2025
8-K 8K EVENT Mar 24, 2026
4 INSIDER TRANSACTION Feb 17, 2026
3 FORM3 Feb 17, 2026
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track NRXP Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking NRXP — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for NRXP
📊 NRXP FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 NRXP Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.